This study aims to determine if Caucasian female thyroid cancer patients aged 20-30 who undergo radioactive iodine ablation (RAI) with the drug Thyrogen have a lower chance of cancer recurrence than those who undergo thyroid hormone withdrawal. The study involves randomly assigning 200 patients to either a control group that undergoes withdrawal or an experimental group that uses Thyrogen. Both groups will be monitored over 10 years to track recurrence rates through medical exams, questionnaires, and scans. The researcher hypothesizes that the Thyrogen group will have statistically significantly lower recurrence rates based on previous studies showing Thyrogen reduces withdrawal side effects.